# Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia

> **NCT06643195** · NA · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 358 (estimated)

## Conditions studied

- AML

## Interventions

- **OTHER:** ImmediateAllogeneic Hematopoietic Stem Cell Transplantation
- **OTHER:** Retreatment

## Key facts

- **NCT ID:** NCT06643195
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 358 (ESTIMATED)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643195, "Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06643195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*